FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination
Authors
Keywords
FTY720, S1P receptor, virus, central nervous system, T lymphocytes, demyelination
Journal
Journal of Neuroinflammation
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-08-19
DOI
10.1186/s12974-014-0138-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
- (2014) Michael P Pender et al. Multiple Sclerosis Journal
- Multiple sclerosis: Prospects and promise
- (2013) Stephen L. Hauser et al. ANNALS OF NEUROLOGY
- Multiple sclerosis
- (2013) Matthew F. Cusick et al. CURRENT OPINION IN RHEUMATOLOGY
- Role of Pathogens in Multiple Sclerosis
- (2013) Jane E. Libbey et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls
- (2013) Giuseppe Mameli et al. JOURNAL OF NEUROIMMUNOLOGY
- Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
- (2013) Jeffrey A. Cohen et al. JOURNAL OF NEUROLOGY
- Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
- (2013) Aran Groves et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk
- (2013) K Strautins et al. Multiple Sclerosis Journal
- Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings
- (2013) JO Virtanen et al. Multiple Sclerosis Journal
- A regenerative approach to the treatment of multiple sclerosis
- (2013) Vishal A. Deshmukh et al. NATURE
- Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice
- (2013) Xiaojie Wang et al. NMR IN BIOMEDICINE
- Fingolimod Therapy for Multiple Sclerosis
- (2013) Mary Willis et al. SEMINARS IN NEUROLOGY
- Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
- (2012) Jason G. Cyster et al. Annual Review of Immunology
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
- (2012) Ernst-Wilhelm Radue ARCHIVES OF NEUROLOGY
- Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod
- (2012) J. N. Ratchford et al. NEUROLOGY
- Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod
- (2012) C. M. Gross et al. NEUROLOGY
- Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome
- (2012) R. Deogracias et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
- (2011) Jeffrey A. Cohen et al. ANNALS OF NEUROLOGY
- Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
- (2011) Jens Ingwersen et al. CLINICAL IMMUNOLOGY
- Fingolimod (FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite
- (2011) Cherilyn R. Strader et al. JOURNAL OF NATURAL PRODUCTS
- The effect of FTY720 in the Theiler's virus model of multiple sclerosis
- (2011) Libin Li et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice
- (2011) Stuart M Cahalan et al. Nature Chemical Biology
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
- (2011) M. Mehling et al. NEUROLOGY
- Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus
- (2011) K. B. Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
- (2010) Veronique E. Miron et al. AMERICAN JOURNAL OF PATHOLOGY
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
- (2010) Volker Brinkmann et al. NATURE REVIEWS DRUG DISCOVERY
- Fingolimod is a potential novel therapy for multiple sclerosis
- (2010) Orhan Aktas et al. Nature Reviews Neurology
- Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis
- (2010) K. S. Carbajal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
- (2010) J. W. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CXCL10 and trafficking of virus-specific T cells during coronavirus-induced demyelination
- (2009) Linda N. Stiles et al. AUTOIMMUNITY
- Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
- (2009) P. O'Connor et al. NEUROLOGY
- Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection
- (2009) Kevin B. Walsh et al. VIROLOGY
- Environmental risk factors in multiple sclerosis
- (2008) M. Pugliatti et al. ACTA NEUROLOGICA SCANDINAVICA
- FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
- (2008) Carolyn A. Foster et al. BRAIN PATHOLOGY
- Could Epstein-Barr Virus or Canine Distemper Virus Cause Multiple Sclerosis?
- (2008) John A. Lincoln et al. NEUROLOGIC CLINICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started